Critical research dossier · Last reviewed 2026-05-16
The Dutch Protocol
How a Dutch experiment on 55 adolescents became the global standard for irreversible hormonal and surgical interventions in minors — and why, after 2020, countries are reversing course one by one.
What this site is about
The Dutch Protocol has grown into one of the most harmful medical experiments in modern adolescent care. It sold puberty suppression as a "reversible pause button" without being able to prove it, relied on a cohort of 55 children, and was then applied worldwide to tens of thousands of adolescents — at the price of irreversible infertility, loss of sexual function and lifelong medicalisation. Since 2020, the Cass Review (UK), SBU (Sweden), COHERE (Finland), NICE and Ukom have systematically examined the evidence base. Their shared conclusion: the evidence is "very low certainty" and the harm is real. The Netherlands — where it all started — is the only originator that has not yet published an independent evidence review.
New — Section VII
The business model — follow the money
Who profits from the Dutch Protocol? €40–60M direct care per year, €80–100M total. Amsterdam UMC (KZcG) €20–25M, UMCG + Radboud €15–25M, private clinics €15–20M. Plus pharma and the waiting-list economy. Read the longread → · Macro analysis →
What actually happened
In the late 1980s, physicians at the VUmc began prescribing puberty blockers to a 13-year-old adolescent. There was no formal protocol, no ethics committee of any substance, no controlled trial. The results of 55 young people — published by de Vries et al. in 2014 — were adopted by the Endocrine Society, WPATH, GIDS (UK), Karolinska, Tampere and hundreds of American clinics as a proven treatment. An unproven experimental pathway became, on the basis of a single study without a control group, the global norm.
Between 2010 and 2020, referral numbers exploded: Tavistock GIDS went from a few hundred to over 5,000 per year. The population shifted radically — from young boys with early-onset dysphoria to teenage girls with late-onset dysphoria and high comorbidity (autism, depression, trauma). The original inclusion and exclusion criteria were set aside internationally. Those who raised doubts were dismissed as "transphobic".
The price became visible in detransition cohorts, in the WPATH Files (in which clinicians admitted among themselves that informed consent in minors is effectively impossible), in court cases like Bell v Tavistock, and in the silent epidemic of young adults with lost fertility and sexual function. When the Cass Review appeared in 2024, the turn was unavoidable: NHS England withdrew the routine provision of puberty blockers.
The evidence in four figures
de Vries 2014 cohort
n = 55
Global policy is built on these 55 adolescents.
Continuation GnRHa → CSH
96–98%
The "diagnostic pause" does not exist in practice — whoever starts, continues.
RCTs
0
Not a single randomised controlled trial supports the protocol.
Evidence rating
"very low"
GRADE assessment by NICE, SBU and the Cass Review.
The dossier
Section I
The Protocol
What the protocol claims to be, where it actually comes from, and which assumptions have never been tested.
Section II
The so-called "scientific basis"
A handful of publications from a single research group, without a control group, without replication — presented as the global norm.
Section III
International rollout
How the experiment became the standard in ten years, and how countries have been reversing course one by one since 2020. See also the comparative table.
Section IV
Evaluations and the turn
Cass Review, SBU, COHERE, Karolinska, Ukom, WPATH Files — what independent researchers found when they actually looked.
Section V
Criticism, harm, legal battles
Methodological and ethical objections, detransition, Bell v Tavistock, Skrmetti, and the defensive response of Amsterdam UMC.
Section VI
Documents & sources
Primary publications, guidelines NL/international, timeline, glossary, people index.
Section VII — New
The business model — follow the money
Who profits from the Dutch Protocol? €40–60M direct care, €80–100M total — academic centres, private clinics, pharma and the waiting-list economy. With macro analysis (four scenarios to 2040).
Quick entry points
For parents
What to ask clinicians, how not to hand over the conversation.
For clinicians
Source pathway for health professionals who want to test the evidence base.
For journalists
Checklists and pitfalls for anyone reporting on this.
Reference
FAQ
15 frequently asked questions with direct dossier references.
Timeline 1972–present
Chronology of publications, policy decisions and evaluations — with an anchor per event.
People index
Profiles of authors, clinicians and evaluators — Cohen-Kettenis, de Vries, Cass, Levine, Bell.
International comparison
Ten countries, one table: GnRHa, CSH, required setting, policy.
Glossary
34 clinical, methodological and institutional terms with a dossier link per term.
Press kit
Key figures, key claim and spokesperson contact for journalists.
Citation: Stichting Genderinfo i.o. (2026). Dutch Protocol — The dossier of a globally exported treatment error. Accessed via https://dutchprotocol.com/. See also /cite/.